Rapport Therapeutics (RAPP) Operating Leases (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Operating Leases data on file, last reported at $8.2 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $8.2 million, up 19.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 million (up 19.81% YoY), and the FY2025 annual result was $8.7 million, up 1081.19% from the prior year.
• Operating Leases declined to $8.2 million in Q1 2026 per RAPP's latest filing, from $8.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $10.1 million in Q2 2025 and troughed at $739000.0 in Q4 2024.
• A 4-year average of $5.3 million and a median of $6.8 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases plunged 49.93% in 2024, then surged 1081.19% in 2025.
• A 4-year view of Operating Leases shows it stood at $1.5 million in 2023, then sank by 49.93% to $739000.0 in 2024, then surged by 1081.19% to $8.7 million in 2025, then fell by 6.2% to $8.2 million in 2026.
• Business Quant data shows RAPP's Operating Leases at $8.2 million in Q1 2026, $8.7 million in Q4 2025, and $9.4 million in Q3 2025.